Table 2.

The effect of SS2 administration on T-cell activity in vivo

Mitogen activity CPM/wellFlow cytometry % fluorescent positive cells
ConALPS CD4 CD8 CD19
Untreated mouse 13,921 ± 1,879  12,453 ± 806    22 ± 1 15 ± 1  56 ± 1  
SS2-treated   3,131 ± 1,224 10,723 ± 1,244   1 ± 1   4 ± 2  63 ± 8 
% Change in activity  −77.5%* −13.9%  −95.6% −78.9%  +12.5%  
P value  .002  NS .001  .001  NS 
Mitogen activity CPM/wellFlow cytometry % fluorescent positive cells
ConALPS CD4 CD8 CD19
Untreated mouse 13,921 ± 1,879  12,453 ± 806    22 ± 1 15 ± 1  56 ± 1  
SS2-treated   3,131 ± 1,224 10,723 ± 1,244   1 ± 1   4 ± 2  63 ± 8 
% Change in activity  −77.5%* −13.9%  −95.6% −78.9%  +12.5%  
P value  .002  NS .001  .001  NS 

Mice (n = 3-4 per group) were given intraperitoneally injections of SS2 (80 g/d) twice daily day 0 to 3. On day 4, splenocytes from treated or untreated control mice were tested for their ability to respond to mitogens conA and LPS using a thymidine incorporation assay. Spontaneous activity (activity in cells not stimulated with mitogen) was 1,260 ± 355 cpm. A sample of the same cells were also tested for the expression of various cell surface markers by flow cytometry as described.

or Create an Account

Close Modal
Close Modal